Log in to search using one of your social media accounts:


Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx ® reinforcing sustained efficacy and safety profile in psoriasis

Novartis, a global leader in Immunology &Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis[1]. Data will be presented at a key medical congress in the second half of 2017.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Related Links:

More News: Allergy & Immunology | Dermatology | Pharmaceuticals | Politics | Psoriasis | Skin | Study